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Smoking Cessation After
Acute Myocardial Infarction*
Neal L. Benowitz, MD,†
Judith J. Prochaska, PHD, MPH‡
San Francisco and Stanford, California
Cigarette smoking produces endothelial dysfunction, con-
stricts blood vessels, activates platelets, creates a chronic
inflammatory state, and causes dyslipidemia (1). These
effects accelerate atherosclerosis, destabilize coronary artery
plaques, and precipitate acute coronary events and sudden
death. Smoking cessation substantially reduces the likeli-
hood of recurrent myocardial infarction, stent or graft
thrombosis, need for revascularization, and cardiovascular
death. Smoking cessation is probably the most important
thing a smoker with acute myocardial infarction can do to
improve future health.
See page 524
Hospitalization for an acute cardiovascular event provides
an important opportunity for quitting smoking. Smokers are
often strongly motivated to quit because the risks of smok-
ing are now personal. Furthermore, most hospitals are
smoke-free, requiring smokers to stop smoking at least
temporarily. The 2008 U.S. Clinical Practice Guidelines for
Treating Tobacco Use and Dependence recommend coun-
seling and medications to help all hospitalized tobacco users
maintain abstinence and to treat withdrawal symptoms (2).
However, smoking-cessation therapy in hospitalized pa-
tients offers a number of challenges. Many patients have
used tobacco for many years and have continued to smoke
despite having cardiovascular risk factors and being coun-
seled to quit, indicating a high level of dependence. The
duration of hospitalization for acute myocardial infarction is
usually brief and the hospital stay is busy, so it is difficult to
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seling. Post-hospitalization, continuity of care for tobacco
treatment, and patient adherence can be challenging, requir-
ing coordination between inpatient and outpatient providers
and facilities.
A 2012 Cochrane review of 50 tobacco treatment trials
for hospitalized patients found that intensive counseling,
initiated during hospitalization with follow-up for at least 1
month after hospital discharge, significantly increased quit
rates (relative risk: 1.37; 95% CI: 1.27 to 1.48; 25 trials) (3).
The Cochrane analysis did not find a significant benefit for less
intensive counseling. Adding nicotine replacement therapy to
intensive counseling increased quitting compared with coun-
seling alone (relative risk: 1.54; 95% CI: 1.34 to 1.79; 6 trials).
Neither bupropion nor varenicline increased quit rates com-
pared with counseling alone, although the number of trials was
small (3 and 2, respectively), so statistical power was limited.
Some clinicians are hesitant to add a smoking-cessation
medication on top of a number of other medications that
have been initiated or continued in the context of myocar-
dial infarction and other medical conditions. In the trial by
Eisenberg et al. (4) in this issue of the Journal, for example,
a majority of the sample was prescribed 6 different heart-
related medications at hospital discharge. Clinicians also
may be concerned about the safety of smoking-cessation
medications in patients with heart disease. Nicotine medi-
cations increase heart rate, blood pressure, and myocardial
contractility and have the potential to cause endothelial
dysfunction and coronary vasoconstriction (1). Bupropion
also has sympathomimetic activity and in higher doses can
increase heart rate and blood pressure. Varenicline is a
relatively selective nicotinic receptor agonist. It acts on the
42 nicotinic cholinergic receptor, which is thought to be
ost important in addiction, and has a lower affinity for the
34 receptor, which mediates cardiovascular effects. There is
little evidence in animal or human experimental studies that
varenicline has cardiovascular effects. However, a number of
cases of cardiovascular events, such as myocardial infarction,
arrhythmia, and syncope, in people taking varenicline have
been reported to regulatory authorities. One meta-analysis of
cardiovascular serious adverse events found a small but signif-
icant increase with varenicline versus placebo (5), whereas a
subsequent larger meta-analysis found no significantly in-
creased risk (6).
The study by Eisenberg et al. (4) is the first published trial
of pharmacotherapy for smoking cessation in a population
composed entirely of patients hospitalized with acute myo-
cardial infarction. This was a multicenter trial involving 392
smokers, two thirds from Canada and the remainder from
Iran and India. Subjects received bupropion in standard
doses or placebo, along with modest behavioral counseling.
The 7-day point prevalence smoking-cessation rates at 1
year were 37.2% for bupropion versus 32% for placebo (p 
0.33). The authors concluded that bupropion is ineffective
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rates when assessed at 3 or 6 months. The authors did find
that among persistent smokers cigarette consumption de-
creased substantially in both treatment groups, with a
decrease on average from 22.8 to 8.4 cigarettes per day. The
authors observed few cardiovascular events during the trial
with no difference by condition. The findings of the study
by Eisenberg et al. (4) are similar to those of the 2 other
published studies of smokers hospitalized for acute cardio-
vascular disease (CVD) treated with bupropion (7,8), both
of which reported fairly high quit rates in the placebo group
(21% and 33% at 1 year), with no significant difference by
condition. Small samples are common across these trials,
and the trial by Eisenberg and colleagues (4) also is limited
with regard to power. Eisenberg and colleagues’ trial
achieved 20% of its registered recruitment goal, so it likely
was underpowered for the intended evaluation of efficacy
and certainly underpowered for safety. Had the reported
cessation rates been observed with the intended sample size
of N  1,500, the treatment differences would have been
ignificant at p  0.05 at all time points. From a public
health perspective, a difference in quit rates of 5% at 1 year
is meaningful in a patient population at high risk for future
cardiovascular events associated with continued tobacco use.
The findings of the trial by Eisenberg et al. (4) and other
studies in hospitalized patients are in contrast to the results
of studies of bupropion and varenicline in outpatients with
stable CVD. Tonstad et al. (9) studied 629 patients with
stable CVD treated with bupropion for 7 weeks versus
placebo and found significantly higher quit rates with
bupropion (point prevalence abstinence 27% vs. 11%, con-
tinuous abstinence 22% vs. 9%, p 0.001 at 1 year). Rigotti
et al. (10) treated 714 smokers with stable CVD with
varenicline or placebo for 12 weeks and found significantly
higher quit rates with varenicline (7-day point prevalence
abstinence 28% vs. 16%; continuous abstinence of 19% vs.
7% at 1 year, both p  0.001).
When comparing abstinence rates, why is it that the
bsolute differences in quit rates between bupropion (and
erhaps varenicline) and placebo seem to be less in patients
ospitalized with acute CVD compared with outpatients
ith stable CVD? Several factors may be involved. First, as
isenberg et al. (4) acknowledged, having approximately
ne third of patients taking placebo quit smoking at 1 year
s fairly high compared with many other trials, suggesting
hat patients who entered this trial were highly motivated to
uit, and per study inclusion criteria, patients had to want to
uit smoking to be enrolled. The finding that those who
ontinued to smoke markedly reduced their cigarette con-
umption is also suggestive of high motivation to reduce
ealth risks. It also may be that patients who experience a
ife-threatening event such as a myocardial infarction, are
ospitalized, and are given a study medication are particu-
arly susceptible to placebo effects. On the other hand, the
bservation that two thirds of the sample continued to
moke after a myocardial infarction is discouraging. It maybe that the acute nature of the hospitalization was insuffi-
cient for maximizing the utility of bupropion (i.e., patients
were discharged before reaching therapeutic blood levels)
and cessation counseling. The patient population is varied,
with two thirds treated in Canada and one third treated in
Iran or India. We know relatively little about smoking
cessation in Iran and India, although the authors report that
the results of the trial were not different when controlling
for country site.
Given the current study’s findings and the extant litera-
ture, what then is the role of cessation pharmacotherapy in
hospitalized smokers? On the basis of the Cochrane 2012
review, there is evidence of benefit from nicotine replace-
ment therapy, but limited evidence to support the routine
prescription of bupropion or varenicline for smoking cessa-
tion in hospitalized smokers. An issue separate from phar-
macotherapy’s impact on long-term smoking cessation is
the use of nicotine medication in the hospital setting to
relieve withdrawal symptoms. Such treatment can reduce
discomfort and enhance compliance with medical treat-
ments and hospital-wide smoking bans. Further, and in
need of greater study, it may be that individualizing phar-
macotherapy according to patient preference and side effects
will enhance long-term cessation.
Given the significant health consequences of smoking
after myocardial infarction, we suggest a minimal goal of
achieving 50% of smokers quitting at long-term follow-up.
Our recommendations, based on available data and The
Joint Commission’s current recommended hospital-wide
standards, are as follows:
1. Effective counseling in the hospital for all smokers, and
not just the minority who are ready to quit. Hospital-
based cessation treatment needs to be proactive, tailored
to readiness to quit, progressive in use of nicotine
replacement for the management of withdrawal
symptoms, and focused on gaining buy-in and build-
ing rapport for continued treatment and patient
adherence post-hospitalization.
2. Effective transition from inpatient to outpatient smoking-
cessation treatment, with a minimum of 1-month follow-up
and preferably longer.
3. Personalized prescription of medication, intended to
relieve withdrawal symptoms in all patients and to sup-
port long-term cessation in patients motivated to quit.
4. Management of co-occurring mental health condi-
tions, such as depression, that are known to be triggers
to smoking relapse and predictive of mortality after
cardiovascular events. A prospective observational
study found that a majority of patients relapsed to
smoking within 6 months after hospitalization for
myocardial infarction (11). Patients treated at a hospital
without a smoking-cessation program (odds ratio [OR]:
1.71) who were not referred for cardiac rehabilitation
(OR: 1.80) and had greater depressive symptoms during
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of patients presenting with heart disease, including smok-
ing status, mental health, and other associated risk be-
haviors (sedentary, alcohol use).
Beyond short-term, acute-care measures, we support
moking-cessation treatment consistent with a chronic dis-
ase model, similar to management of other diseases, such
s hypertension and diabetes. In this type of approach, all
atients are counseled with the expectation that sooner or
ater they will quit smoking as an essential element of their
ealth care (12). Pharmacotherapy is prescribed in an individ-
alized and flexible way to initiate and sustain abstinence, with
edications combined and/or doses adjusted to relieve with-
rawal symptoms and minimize urges to smoke. Relapse to
moking is anticipated, and patients are counseled about
oth relapse prevention and re-engagement in the quitting
rocess after relapse. The observation that cigarette con-
umption was substantially reduced in the trial by Eisenberg
t al. (4) suggests that these smokers remained concerned
bout smoking as a health risk and may have lowered their
evel of tobacco dependence, making them more amenable
o later smoking cessation within a chronic disease–
anagement program.
A continuing care model for smoking-cessation interven-
ion for patients hospitalized with CVD has been described
n Canada, named the “Ottawa Model” (13). The Ottawa
odel intervention begins with customized counseling and
harmacotherapy for all smokers while in the hospital.
ost-hospitalization follow-up is done using an interactive
oice-responsive telephone system, with automated phone
alls at frequent intervals for up to 180 days after discharge.
elapse counseling is provided as needed. Counselors are
vailable to respond to particular patient needs. This ap-
roach is reported to result in 29% continuous abstinence at
months across institutions and as high as 44% at one
nstitution.
In conclusion, the standard of care for managing patients
fter myocardial infarction should include not only blood
ressure and lipid management but also smoking cessation.
t present, the quit rates for smokers after myocardial
nfarction are higher than those for the general population
f smokers, yet given the enormous health risks, still much
oo low. Increasing quit rates will likely require a combina-
ion of counseling and personalized medications, with a
hronic disease management approach. Future studies ofmoking cessation in hospitalized patients should be con-
ucted to test the effectiveness of such multicomponent
nterventions.
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